Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers

Abstract

BACKGROUND:

The most important anti-tumor immune response is mediated by T lymphocytes. The interaction of programmed death-1 ligand-1 (PD-L1) with its receptor provides an inhibitory signal in T lymphocytes activation and proliferation.

OBJECTIVE:

This study aimed to investigate whether polymorphisms of PD-L1 were associated with the risk and prognosis of esophageal squamous cell carcinoma (ESCC) in a high-incidence population from Northern China.

METHODS:

PD-L1 rs2890658 A/C and rs4143815 C/G single nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction ligase detection reaction (PCR-LDR) method in 575 ESCC patients and 577 healthy controls.

RESULTS:

There was no significant difference in the genotype frequencies of these two SNPs between the ESCC patients and the healthy controls. However, for rs2890658 A/C SNP, compared with the C/C genotype, the A/C genotype increased the risk of ESCC for the smokers (OR $=$ 1.513, 95% CI $=$ 1.006–2.287). Among the 575 ESCC patients, the survival information of 202 ESCC patients was collected. Neither the rs2890658 A/C SNP nor the rs4143815 C/G SNP was associated with the survival of ESCC patients.

CONCLUSIONS:

PD-L1 rs2890658 A/C SNP might be used as risk marker of the susceptibility to ESCC for the Han nationality in a high-incidence population from Northern China.

Keywords

Esophageal squamous cell carcinoma programmed death-1 ligand-1 polymorphism prognosis risk

1. Introduction

Esophageal cancer was the sixth leading cause of cancer-related deaths worldwide in 2012 [1]. Cixian of Hebei Province is one of the high-incidence regions for esophageal cancer in China. With the development of surgical techniques, radiotherapy, chemotherapy and immunotherapy, incidence and mortality rate of esophageal cancer has declined during the past forty years in this region [2]. However, esophageal cancer remains a major public health burden. Thereby, it is urgent to identify the risk factors and prognostic markers of esophageal cancer for the population in this high-incidence region.

Table 1
Primer sequences and probe sequences in PCR-LDR reactions

SNP	Primer	Primer sequence	PCR product length
rs2890658	Forward	5 ${}^{\prime}$ -agcaagaggaagtgaaataatc-3 ${}^{\prime}$
	Reverse	5 ${}^{\prime}$ -tggtgctggggctaaattctg-3 ${}^{\prime}$	192 bp
rs4143815	Forward	5 ${}^{\prime}$ -cctccaagcaaatcatccat-3 ${}^{\prime}$
	Reverse	5 ${}^{\prime}$ -atacataaatactgtcccgtt-3 ${}^{\prime}$	164 bp
SNP	Probe	Probe sequence	LDR product length
rs2890658	Modify	5 ${}^{\prime}$ -P-gccatttaatagtgagcagccactc-FAM-3 ${}^{\prime}$
	A	5 ${}^{\prime}$ -aagaggaagtgaaataatcaaggca-3 ${}^{\prime}$	50 bp
	C	5 ${}^{\prime}$ -tttaagaggaagtgaaataatcaaggcc-3 ${}^{\prime}$	53 bp
rs4143815	Modify	5 ${}^{\prime}$ -P-ttttctgcatgactgagagtctcagtttttt-FAM-3 ${}^{\prime}$
	C	5 ${}^{\prime}$ -tttttttttgcctccactcaatgcctcaatttc-3 ${}^{\prime}$	64 bp
	G	5 ${}^{\prime}$ -ttttttttttttgcctccactcaatgcctcaatttg-3 ${}^{\prime}$	67 bp

Human immune system plays a critical role in the development and progression of various tumors. The most important anti-tumor immune response is mediated by T lymphocytes. Programmed death-1 ligand-1 (PD-L1, also known as CD274 or B7-H1) is located on the chromosome 9p24.2 and encodes a type I transmembrane protein with 290 amino acids. PD-L1 is expressed on activated T lymphocytes, B lymphocytes, dendritic cells, macrophages and some immune-privileged non-hematopoietic tissues [3, 4]. The interaction of PD-L1 with its receptor, PD-1, provides an inhibitory signal in T lymphocytes activation and proliferation, suppresses cytokine secretion, induces T lymphocytes apoptosis and maintains peripheral tolerance [5, 6, 7]. The expression of PD-L1 has also been reported in most human cancers including esophageal cancer [8, 9, 10, 11, 12]. Cancer-cell associated PD-L1 may contribute to tumor evasion from host immune [13, 14]. Increasing evidences showed that the expression of PD-L1 could be used as an indicator of poor prognosis for cancer patients [8, 9, 10, 11, 12]. Considering the important role of PD-L1 in immune regulation and tumor pathogenesis, we genotyped two single nucleotide polymorphisms (SNPs) (rs2890658 and rs4143815) in PD-L1 to explore the association of these two SNPs with the risk and prognosis of esophageal squamous cell carcinoma (ESCC) in a high-incidence population from Northern China.

2. Materials and methods

2.1 Study subjects

The study consisted of 575 ESCC patients and 577 healthy controls. All of the study subjects were ethnically homogeneous (of Han descent) and permanent residents of Cixian. All of the patients and healthy controls were recruited during an endoscopic screening campaign between 2009 and 2014. The patients had histologically confirmed ESCC; self-reported, cancer-free subjects who were confirmed to be without upper gastrointestinal cancer (UGIC) by endoscopy were selected as healthy controls. Information on the sex, age, smoking habits and family history of UGIC from the cancer patients and healthy controls was obtained by two professional interviewers directly after blood sampling. Smokers were defined as those who formerly or currently smoked no less than five cigarettes per day for at least 2 years. Individuals who had at least one first-degree relative or at least two second-degree relatives who had esophageal/cardiac/gastric cancer were defined as having a family history of UGIC. In addition, the ESCC patients were followed based on survival information. Two hundred and two ESCC patients with survival information were included in the survival analysis. The study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University. The written informed consent forms were obtained from all recruited subjects.

Table 2
Distribution of selected characteristics in ESCC patients and healthy controls

Group	Control	ESCC	$\chi^{2}$	$P$
	$n$ (%)	$n$ (%)
Sex
Male	377 (65.3)	376 (65.4)
Female	200 (34.7)	199 (34.6)	0.000	0.985
Age
$\leqslant$ 60 years	314 (54.4)	311 (54.1)
$>$ 60 years	263 (45.6)	267 (45.9)	0.013	0.910
Smoking status
Non-smoker	346 (60.0)	329 (57.2)
Smoker	231 (40.0)	246 (42.8)	0.896	0.344
Family history of UGIC
Negative	356 (61.7)	308 (53.6)
Positive	221 (38.3)	267 (46.4)	7.802	0.005

Table 3

Association between PD-L1 gene SNPs and susceptibility to ESCC

SNP/Group	Control $n$ (%)	ESCC $n$ (%)	$P$	OR (95% CI)*
rs2890658 A/C SNP
Overall
C/C	418 (72.4)	396 (68.9)		1.000
A/C	144 (25.0)	161 (28.0)	0.218	1.180 (0.906 $\sim$ 1.537)
A/A	15 (2.6)	18 (3.1)	0.506	1.255 (0.617 $\sim$ 2.551)
Smoker
C/C	172 (74.5)	164 (66.7)		1.000
A/C	52 (22.5)	75 (30.5)	0.049	1.513 (1.006 $\sim$ 2.287)
A/A	7 (3.0)	7 (2.8)	0.930	1.010 (0.343 $\sim$ 2.975)
rs4143815 C/G SNP
C/C	203 (35.2)	211 (36.7)		1.000
C/G	289 (50.1)	277 (48.2)	0.531	0.918 (0.712 $\sim$ 1.184)
G/G	85 (14.7)	87 (15.1)	0.932	0.988 (0.689 $\sim$ 1.415)

*: Adjusted for sex, age, smoking status and UGIC family history (the stratified factor in each stratum excluded).

Table 4

ESCC patients’ characteristics and survival of ESCC patients

Group	Patients $n$ (%)	Deaths $n$ (%)	MST* (months)	Log-rank P	HR (95% CI)
Sex
Male	135 (66.8)	50 (37.0)	28.4		1.000
Female	67 (33.2)	19 (28.4)	30.4	0.227	0.724 (0.427 $\sim$ 1.229)
Age
$\leqslant$ 60 years	102 (50.5)	33 (32.4)	28.9		1.000
$>$ 60 years	100 (49.5)	36 (36.0)	29.2	0.694	1.099 (0.685 $\sim$ 1.762)
Smoking status
Non-smoker	92 (45.5)	27 (29.3)	29.8		1.000
Smoker	110 (54.5)	42 (38.2)	28.5	0.229	1.342 (0.827 $\sim$ 2.176)
Family history of UGIC
Negative	128 (63.4)	47 (36.7)	28.5		1.000
Positive	74 (36.6)	22 (29.7)	30.1	0.306	0.770 (0.464 $\sim$ 1.277)

*: mean survival time.

2.2 DNA extraction

Five milliliters of venous blood was drawn from each subject in Vacutainer tubes containing ethylene diamine tetra acetic acid and stored at 4 ${}^{\circ}$ C. After sampling, genomic DNA was extracted within 1 week by proteinase K (Merck, Darmstadt, Germany) digestion, followed by a salting out procedure according to the method published by Miller et al. [15].

2.3 Polymorphism genotyping

The genotypes of PD-L1 polymorphisms were determined by the Shanghai Generay Biotech Co., Ltd. (Shanghai, China) using the polymerase chain reaction ligase detection reaction (PCR-LDR) method. The primers for amplification and the probes for LDR were shown in Table 1.

2.4 Statistical analysis

Table 5
PD-L1 gene SNPs and survival of ESCC patients

SNP	Patients $n$ (%)	Deaths $n$ (%)	MST (months)	Log-rank P	HR (95% CI)*
rs2890658 A/C SNP
C/C	139 (68.8)	46 (33.1)	29.2		1.000
A/C	57 (28.2)	22 (38.6)	28.4		1.283 (0.767 $\sim$ 2.147)
A/A	6 (3.0)	1 (16.7)	32.0	0.532	0.510 (0.070 $\sim$ 3.736)
rs4143815 C/G SNP
C/C	69 (34.2)	21 (30.4)	30.3		1.000
C/G	101 (50.0)	38 (37.6)	27.9		1.414 (0.825 $\sim$ 2.424)
G/G	32 (15.8)	10 (31.3)	30.0	0.513	1.034 (0.486 $\sim$ 2.200)

*: Adjusted for sex, age, smoking status and UGIC family history.

Statistical analysis was performed using the SPSS ver. 22.0 software package (SPSS, Chicago, IL, USA). $P<$ 0.05 was considered significant for all statistical analyses. A Hardy-Weinberg equilibrium analysis was performed by comparing the observed and expected genotypic frequencies in the control group using the $\chi^{2}$ test. Comparison of the genotype distribution in the patients and healthy controls was performed by two-sided contingency tables using the $\chi^{2}$ test. The odds ratio (OR) and 95% confidence interval (CI) for genotypic-specific risk were calculated using an unconditional logistic regression model and adjusted accordingly by sex, age, smoking status and family history of UGIC. Survival time was calculated from the date of ESCC diagnosis to the date of death or last follow-up. The associations of survival time with demographic characteristics and PD-L1 gene SNPs were estimated using the Kaplan-Meier method and log-rank test. Univariate or multivariate Cox regression analysis was fitted to estimate the crude hazard ratios (HRs), adjusted HRs, and 95% confidence intervals (CIs).

3. Results

Figure 1.

Kaplan-Meier survival curves for ESCC patients by the genotypes of PD-L1 gene SNPs.

3.1 Association between PD-L1 polymorphisms and the risk of ESCC

The mean age of the ESCC patients and the healthy controls were 60.3 $\pm$ 8.5 years and 60.1 $\pm$ 8.2 years, respectively. The percentage of male subjects in the healthy controls (65.3%) was similar to that of the ESCC cases (65.4%). No significant difference was found in the distribution of age and sex between the ESCC patients and the healthy controls ( $P=$ 0.910 and 0.985), suggesting that frequency matching was adequate. The proportion of smokers among the ESCC cases was slightly higher than that among the controls, but the difference was not significant ( $P=$ 0.344). The frequency of a positive family history of UGIC in ESCC patients was 46.4%, which was significantly higher than that of the healthy controls ( $P=$ 0.005) (Table 2). Therefore, UGIC family history increased the risk of ESCC (the sex-, age- and smoking status-adjusted OR $=$ 1.395, 95% CI $=$ 1.101–1.764).

The genotype distributions of PD-L1 rs2890658 A/C and rs4143815 C/G SNPs in the healthy controls were consistent with Hardy–Weinberg equilibrium ( $P=$ 0.541 and 0.275). The C/C, A/C and A/A genotype frequencies of the rs2890658 A/C SNP in the ESCC patients and the healthy controls were 68.9%, 28.0%, 3.1% and 72.4%, 25.0%, 2.6%. There was no significant difference in the genotype frequencies between the ESCC patients and the healthy controls (Table 3). However, when stratified by sex, age, smoking status and UGIC family history, compared with the C/C genotype, the A/C genotype increased the risk of ESCC for the smokers (the sex-, age- and UGIC family history-adjusted OR $=$ 1.513, 95% CI $=$ 1.006–2.287) (Table 3). The C/C, C/G and G/G genotype frequencies of the rs4143815 C/G SNP in the ESCC patients and the healthy controls were 36.7%, 48.2%, 15.1% and 35.2%, 50.1%, 14.7%. The rs4143815 C/G SNP did not modify the risk of ESCC overall (Table 3) or in the stratified analyses (data not shown).

3.2 Association between PD-L1 polymorphisms and the survival of ESCC patients

The mean age of the 202 ESCC patients with survival information was 60.4 $\pm$ 7.9. Sex, age, smoking status and UGIC family history were not associated with the survival time of the ESCC patients (Table 4). Neither the rs2890658 A/C SNP nor the rs4143815 C/G SNP was associated with the survival of ESCC patients (Table 5, Fig. 1).

4. Discussion

In this molecular epidemiological study, for the first time, we investigated whether PD-L1 polymorphisms contribute to susceptibility to ESCC and to the prognosis of ESCC patients. We found that UGIC family history increased the risk of ESCC, which suggested that genetic background played an important role in the development of ESCC. Compared with PD-L1 rs2890658 A/C SNP C/C genotype, A/C genotype elevated the risk of ESCC for the smokers. PD-L1 rs4143815 C/G SNP had no effect on susceptibility to ESCC. In addition, neither rs2890658 A/C SNP nor rs4143815 C/G SNP was associated with the prognosis of ESCC patients.

PD-L1 rs2890658 A/C SNP is situated within the third intron. The function of introns seems to less important. In fact, some studies identified transcription regulation element on the introns of the human gene [16, 17, 18, 19] and found intronic variants might affect disease susceptibility [20, 21]. PD-L1 rs2890658 A/C SNP has been reported to be associated with the risk of non-small cell lung cancer and Graves’ disease [22, 23, 24, 25]. Similarly, this SNP also influenced the susceptibility to ESCC. To date, there is no report about functional study of rs2890658 A/C SNP. The observed association with rs2890658 A/C SNP suggested that this SNP being directly functional or being in linkage disequilibrium with another functional variant [26]. However, rs2890658 A/C SNP was not related to the risk of some autoimmune diseases [27, 28] and the prognosis of ESCC patients.

The rs4143815 C/G SNP is located on the 3 ${}^{\prime}$ -untranslated region (3 ${}^{\prime}$ -UTR) of PD-L1. MicroRNA (miRNA), an endogenous noncoding RNA of 20–25 nucleotides, can regulate expression of the target gene at the post-transcription or translation level by interacting with the 3 ${}^{\prime}$ -UTR of the target mRNA [29]. Wu et al. [10] evaluated the expression of PD-L1 in 102 gastric cancer tissues and 10 normal gastric tissues by immunohistochemistry method. The results indicated that PD-L1 expression could be detected in 42.2% of gastric cancer tissues but not in normal gastric tissues. In addition, PD-L1 expression predicted a bad prognosis of the patients with gastric cancer. Subsequently, a series of experiments were conducted to define the regulatory mechanisms for PD-L1 overexpression. Wang et al. [30] reported that a G to C mutation at the 3 ${}^{\prime}$ -UTR of PD-L1 mRNA disrupted miRNA-570 binding and led to PD-L1 overexpression, which implied rs4143815 C/G SNP might be functional. Therefore, it is reasonable that rs4143815 C/G SNP was associated with the risk of gastric cancer [31]. However, this correlation was not detected in our study on ESCC. Possibly, the same polymorphism may have a different influence on carcinogenesis of different cancers, which was also observed in our other study [32, 33]. Human immune system is crucial not only in the development and progression of tumor but also in cancer therapy. T lymphocytes play a critical role in antitumor immune. Lee et al. [34] investigated whether polymorphisms of PD-L1 gene providing inhibitory signal for T lymphocytes activation could predict the clinical outcome of patients with advanced non-small cell lung cancer after chemotherapy and found that rs4143815 C/G SNP was significantly associated with better response under additive model for G allele. The results helped to identify patients who would benefit from chemotherapy and to save patients from unnecessary toxicities. Lee et al. [34] also assessed the association between polymorphisms of PD-L1 and overall survival in patients with non-small cell lung cancer. However, rs4143815 C/G SNP could not be used a predictor for the non-small cell lung cancer patients’ prognosis. Likewise, similar result was found in our study.

In this population-based case-control study, all of the participants were of ethnically homogeneous Han nationality, which might exclude selection bias and avoid introducing ethnicity-driven bias. However, there were some limitations. Firstly, only two SNPs were involved in present study. Secondly, partial results, although adjusted by sex, age, smoking status and UGIC family history, were acquired based on stratified analyses with a limited sample size. Therefore, the relation between other SNPs of PD-L1 and ESCC should be investigated in additional studies with a larger sample size in a population from Cixian high-incidence region or other regions.

In conclusion, this study for the first time assessed the association of PD-L1 polymorphisms with the development and prognosis of ESCC in a high-incidence population from Northern China. The results indicated that PD-L1 rs2890658 A/C SNP was associated with the risk of ESCC for smokers. Therefore, the smokers with rs2890658 A/C SNP A/C genotype should receive regular upper gastrointestinal fiber tests, which help to facilitate early diagnosis and early treatment of ESCC.

Footnotes

Acknowledgments

We would like to thank Zhi-feng Chen for help with sample collection. We gratefully acknowledge Guo-hui Song and Lei Wang for help with data collection. This study was funded by grants from the Financial Department of Hebei Province [No. (2012)2056].

Conflict of interest

The authors declare no conflicts of interest.

References

GLOBOCAN 2012. Lyon: IARC. Available online: http://globocan.iarc.fr/.

Song

et al., Incidence and mortality rate of esophageal cancer has decreased during past 40 years in Hebei Province, China, Chin J Cancer Res 27 (2015), 562–571.

Keir

M.E.

Liang

S.C.

Guleria

et al., Tissue expression of PD-L1 mediates peripheral T cell tolerance, J Exp Med 203 (2006), 883–895.

Zou

and Chen

, Inhibitory b7-family molecules in the tumour microenvironment, Nat Rev Immunol 8 (2008), 467–477.

Freeman

G.J.

Long

A.J.

Iwai

et al., Engagement of the PD-1 immunoinhibitory receptor by a novel b7 family member leads to negative regulation of lymphocyte activation, J Exp Med 192 (2000), 1027–1034.

Latchman

Wood

C.R.

Chernova

et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol 2 (2001), 261–268.

Nishimura

and Honjo

, PD-1: An inhibitory immunoreceptor involved in peripheral tolerance, Trends Immunol 22 (2001), 265–268.

Thompson

R.H.

Gillett

M.D.

Cheville

J.C.

et al., Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target, Proc Natl Acad Sci U S A 101 (2004), 17174–17179.

Ohigashi

Sho

Yamada

et al., Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer, Clin Cancer Res 11 (2005), 2947–2953.

10.

Zhu

Jiang

Zhao

Zhang

X.G.

and Xu

, Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochem 108 (2006), 19–24.

11.

Ghebeh

Mohammed

Al-Omair

et al., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia 8 (2006), 190–198.

12.

Nomi

Sho

Akahori

et al., Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res 13 (2007), 2151–2157.

13.

Dong

Strome

S.E.

Salomao

D.R.

et al., Tumor-associated B7-H1 promotes t-cell apoptosis: A potential mechanism of immune evasion, Nat Med 8 (2002), 793–800.

14.

Iwai

Ishida

Tanaka

Okazaki

Honjo

and Minato

, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc Natl Acad Sci U S A 99 (2002), 12293–12297.

15.

Miller

S.A.

Dykes

D.D.

and Polesky

H.F.

, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res 16 (1988), 1215–1215.

16.

Dean

and Clark

I.M.

, Transcriptional regulation of the human tissue inhibitor of metalloproteinases-1: Mapping transcriptional control in intron-1, Ann N Y Acad Sci 878 (1999), 510–511.

17.

Kawada

Moriyama

Ando

et al., Role of intron 1 in smooth muscle alpha-actin transcriptional regulation in activated mesangial cells in vivo, Kidney Int 55 (1999), 2338–2348.

18.

Naukkarinen

Gentile

Soro-Paavonen

et al., USF1 and dyslipidemias: Converging evidence for a functional intronic variant, Hum Mol Genet 14 (2005), 2595–2605.

19.

Surinya

K.H.

Cox

T.C.

and May

B.K.

, Identification and characterization of a conserved erythroid-specific enhancer located in intron 8 of the human 5-aminolevulinate synthase 2 gene, J Biol Chem 273 (1998), 16798–16809.

20.

Tokuhiro

Yamada

Chang

et al., An intronic SNP in a RUNX1 binding site of SLC22A4 encoding an organic cation transporter is associated with rheumatoid arthritis, Nat Genet 35 (2003), 341–348.

21.

Prokunina

Castillejo-López

Oberg

et al., A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans, Nat Genet 32 (2002), 666–669.

22.

Liu

Zhu

et al., Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a chinese population, Int J Clin Exp Med 8 (2015), 16585–16591.

23.

Chen

Y.B.

C.Y.

Chen

and Huang

J.A.

, Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a chinese population, Asia Pac J Clin Oncol 10 (2014), e1–e6.

24.

Cheng

Zheng

Zhu

et al., PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer, Int J Biol Markers 30 (2015), e364–e368.

25.

Hayashi

Kouki

Takasu

Sunagawa

and Komiya

, Association of an a/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with graves’ disease in japanese patients, Eur J Endocrinol 158 (2008), 817–822.

26.

Milne

R.L.

Ribas

González-Neira

et al., ERCC4 associated with breast cancer risk: A two-stage case-control study using high-throughput genotyping, Cancer Res 66 (2006), 9420–9427.

27.

Meng

Guo

Hou

Jiang

Kijlstra

and Yang

, Lack of an association of PD-1 and its ligand genes with behcet’s disease in a chinese han population, PLoS One e25345. 6 (2011).

28.

Huang

C.H.

Wong

R.H.

Wei

J.C.

et al., Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis, Rheumatology (Oxford) 50 (2011), 1809–1813.

29.

Bartel

D.P.

, MicroRNAs: Target recognition and regulatory functions, Cell 136 (2009), 215–233.

30.

Wang

Sun

et al., A frequent somatic mutation in CD274 3′-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding, Hum Mutat 33 (2012), 480–484.

31.

Wang

Mao

et al., A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma, Hum Genet 132 (2013), 641–648.

32.

Guo

Zhou

R.M.

Wan

L.L.

et al., Polymorphisms of the DNA repair gene xeroderma pigmentosum groups A and C and risk of esophageal squamous cell carcinoma in a population of high incidence region of north china, J Cancer Res Clin Oncol 134 (2008), 263–270.

33.

Dong

Guo

Zhou

et al., Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in north china, J Clin Gastroenterol 42 (2008), 910–915.

34.

Lee

S.Y.

Jung

D.K.

Choi

J.E.

et al., PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy, Sci Rep 6 (2016), 25952.